Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas

Autor(es)

Acar, Vitoria ^[1] ; Couto Fernandez, Fabio Leite ^[2] ; Buscariolo, Fabio Fabian ^[1] ; Novais, Adriana Alonso ^[3] ; Matheus Pereira, Roseli Aparecida ^[4] ; Pires de Campos Zuccari, Debora Aparecida ^[5]

Afiliação do(s) autor(es)

^[1] Sao Jose do Rio Preto Med Sch FAMERP, Sao Jose Do Rio Preto, SP - Brazil

^[2] Sao Jose do Rio Preto Med Sch FAMERP, Dept Clin Med, Sao Jose Do Rio Preto, SP - Brazil

^[3] Sao Jose do Rio Preto Med Sch FAMERP, Canc Mol Res Lab, Sao Jose Do Rio Preto, SP - Brazil

^[4] Sao Jose do Rio Preto Med Sch FAMERP, Dept Nursing, Sao Jose Do Rio Preto, SP - Brazil

^[5] Sao Jose do Rio Preto Med Sch FAMERP, Dept Mol Biol, Sao Jose Do Rio Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: CLINICAL MEDICINE & RESEARCH; v. 19, n. 4, p. 183-191, DEC 1 2021.
• Citações Web of Science: 0

Resumo

Prostate cancer is the second most common neoplasm among men, with a high mortality rate in advanced stages. Poly (ADP-ribose) polymerase (PARP) plays an important role in repair to DNA damage, being associated with resistance to tumor cell death. Conversely, Caspase-3 is a crucial mediator of programmed cell death, being highly expressed in apoptotic cells.The aim of the present study was to characterize the expression of PARP and Caspase-3 by immunohistochemistry in patients with advanced prostate cancer. PARP and Caspase-3 were independently correlated to patients' evolution, in accordance with the classification of prognostic groups.The increase in PARP expression was positively correlated with tumor patients with poor prognosis (P < 0.0001). In contrast, a decrease in Caspase-3 expression was identified in patients with poor prognosis, when compared with prostate cancer patients with good prognosis (P = 0.0007). Numerically, 92.3% of patients previously classified with poor prognosis showed higher PARP expression, while 93.75% of patients previously classified with good prognosis showed higher levels of Caspase-3.We conclude that PARP and Caspase-3 are potential prognostic markers for prostate cancer patients with different prognosis. (AU)

• Processo FAPESP: 19/11381-1 - Avaliação imuno-histoquímica de PARP e caspase-3 como marcadores prognósticos em carcinomas de próstata
• Beneficiário: Vitoria Acar
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica